natgillin/translations-raw huggingface dataset:
Antibodies to efalizumab were detected in only 6% of patients evaluated.
Protitelesa na efalizumab so odkrili pri samo 6 % proučevanih bolnikov.
Patients have recovered after discontinuation of Raptiva, therefore Raptiva should be stopped following the diagnosis of inflammatory polyradiculoneuropathy.
Po prekinitvi uporabe Raptive so bolniki okrevali, zato se mora ob diagnozi vnetne poliradikulonevropatije prenehati z uporabo Raptive.
Patients with specific forms of psoriasis like guttate, erythrodermic or pustular psoriasis as sole or
Bolniki s specifičnimi oblikami psoriaze kot so gutatna, eritrodermična ali pustulozna psoriaza bodisi sama ali kot predominantna oblika psoriaze.
Efalizumab is a recombinant humanized monoclonal antibody that binds specifically to the CD11a subunit of LFA-1 (lymphocyte function-associated antigen-1), a leukocyte cell surface protein.
Efalizumab je rekombinantno humanizirano monoklonalno protitelo, ki se specifično veže za CD11a podenoto LFA-1 (limfocitni funkcijski antigen-1), protein na površini celice levkocita.
By preventing LFA-1/ICAM binding, efalizumab may alleviate signs and symptoms of psoriasis by inhibiting several
S preprečevanjem vezave LFA-1/ICAM, lahko efalizumab ublaži znake in simptome psoriaze z inhibicijo več stopenj imunološke kaskade.
Efalizumab is an IgG1 kappa immunoglobulin, containing human constant region sequences and murine light- and heavy-chain complementary determining
Efalizumab je IgG1 kapa imunoglobulin, ki vsebuje konstantno humano regijo in komplementarnost določujočo regijo, murinski lahki in težki verigi.
These common side effects have not been clearly associated with Raptiva but have been observed when using it.
Ni jasne povezave med temi pogostimi neželenimi učinki in zdravilom Raptiva, vendar so bili opaženi med njeno uporabo.
• A relapse or flare or strong worsening of psoriasis or red, inflamed psoriatic plaques, sometimes with swelling of your arms or legs or joint inflammation, especially after stopping Raptiva.
- Relaps (ponovitev) ali zagon ali močno poslabšanje psoriaze ali rdeči, vnetni psoriazni plaki, včasih z oteklostjo rok ali nog ali vnetjem sklepov, zlasti po prenehanju uporabe zdravila Raptiva.
Therapy may be continued only in those patients who respond adequately to treatment.
Zdravljenje se lahko nadaljuje samo pri bolnikih z zadostnim odzivom na zdravljenje.
- If you develop signs and symptoms associated with anaemia (a reduction in red blood cells which can make the skin pale and cause weakness or breathlessness) while undergoing treatment, please contact your doctor who will determine if it is necessary for you to stop using
- Če razvijete znake ali simptome povezane z anemijo (zmanjšanje števila rdečih krvnih celic, ki lahko povzroči bledo polt, slabotnost ali zasoplost) med zdravljenjem z zdravilom Raptiva, se posvetujte z zdravnikom, ki bo določil, ali je potrebno da prenehate z uporabo zdravila Raptiva.
In case re-treatment with Raptiva is indicated the same guidance should be followed as under Posology and method of administration.
Če je potrebno ponovno zdravljenje z Raptivo, je treba upoštevati enake smernice kot so navedene v poglavju Odmerjanje in način uporabe.
Cases occurring after discontinuation were observed both in patients responding or not responding to Raptiva treatment.
Primere pojava po prekinitvi zdravljenja so opazili tako pri odzivnih kot pri neodzivnih bolnikih na zdravljenje z Raptivo.
Use in the elderly (≥ 65 years)
Odmerjanje za odrasle (18 - 64 let) in starejše (≥ 65 let)
Consequently, if any serious hypersensitivity or allergic reaction occurs, Raptiva should be discontinued immediately and appropriate therapy initiated (see sections 4.3 and 4.8).
Zato se mora v primeru pojava hude preobčutljivostne ali alergijske reakcije takoj prekiniti z uporabo Raptive in uvesti ustrezno zdravljenje (glejte poglavji 4.3 in 4.8).
IMP24011: p-values compared efalizumab with placebo using logistic regression including baseline PASI score, prior treatment for psoriasis and geographical region as covariates.
IMP24011: p-vrednosti primerjave efalizumaba s placebom z uporabo logistične regresije vključujoč izhodiščni PASI izvid, predhodno zdravljenje psoriaze in geografsko regijo kot kovariable.
Sites for self-injection include the buttocks, thigh, abdomen or upper arm.
Mesta za samoinjiciranje vključujejo zadnjico, stegna, trebuh ali zgornji del roke.
Raptiva can be used in combination with topical corticosteroids.
Zdravilo Raptiva se lahko uporablja v kombinaciji s kortikosteroidi za lokalno zdravljenje.
In a patient with history of clinically significant recurring infections, Raptiva should be used with caution.
Pri bolnikih, ki so imeli v preteklosti klinično pomembne rekurentne okužbe, je treba Raptivo uporabljati previdno.
Slight elevation in absolute neutrophil count and eosinophil count were observed but in a smaller proportion
Blag dvig absolutnega števila nevtrofilcev in eozinofilcev so opazili, vendar pri majhnem deležu bolnikov.
(n=342) b p-values compared efalizumab with placebo using logistic regression including baseline PASI score, prior treatment for psoriasis and geographical region as covariates.
(n=342) b p-vrednosti primerjave efalizumaba s placebom z uporabo logistične regresije vključno z izhodišnim PASI izvidom, predhodnim zdravljenjem psoriaze in geografsko regijo kot
Cases of arthritis have been observed during treatment or after discontinuation of Raptiva.
Opazili so primere artritisa med zdravljenjem ali po prekinitvi zdravljenja z Raptivo.
Raptiva is injected just under the skin (subcutaneous).
Zdravilo Raptiva se injicira tik pod kožo (subkutano).
Hypersensitivity to efalizumab or to any of the excipients.
Preobčutljivost za efalizumab ali katerokoli pomožno snov.
• Very slowly push down on the syringe plunger to inject all the solvent into the Raptiva vial.
• Zelo počasi pritisnite navzdol bat injekcijske brizge, da injicirate ves vehikel v vialo Raptiva.
In large placebo-controlled clinical studies, the percentage of patients experiencing an adverse event suggestive of hypersensitivity, including urticaria, rash and allergic reactions was slightly higher in the Raptiva group (8%) than in the placebo group (7%).
V velikih s placebom kontroliranih kliničnih študijah, je bil delež bolnikov, ki so doživeli neželene dogodke, ki bi lahko kazali na preobčutljivost, vključno z urtikarijo, izpuščajem in alergijskimi reakcijam, rahlo večji v skupini bolnikov, ki so prejemali Raptivo (8 %) kot v skupini bolnikov, ki so prejemali placebo (7 %).
Reconstitution of the singleuse vial with 1.3 ml of the supplied water for injections yields approximately 1.5 ml of solution to deliver 100 mg per 1 ml of Raptiva.
Po rekonstituciji viale za enkratno uporabo z 1,3 ml priložene vode za injekcije nastane približno 1,5 ml raztopine, kar zagotavlja odmerek Raptive 100 mg v 1 ml.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Raptiva 100 mg/ml
IME ZDRAVILA IN POT(I) UPORABE Raptiva 100 mg/ml
Thrombocytopenia may occur during Raptiva treatment and may be associated with clinical signs such as echymoses, spontaneous bruising or bleeding from muco-cutaneous tissues.
Med zdravljenjem z Raptivo se lahko pojavi trombocitopenija in je lahko povezana s kliničnimi znaki kot so ehimoze, spontane modrice ali krvavitve sluznic in kože.
If you administer Raptiva, please read the following instructions carefully and follow then step by
Če si sami injicirate zdravilo Raptiva, prosimo, da natančno preberete naslednja navodila in jih nato
In the target population studied in study IMP24011, the infection rate in Raptiva-treated patients was approximately 25.7% versus 22.3% in placebo-treated patients.
V ciljni populaciji, ki so jo proučevali v študiji IMP24011, je bil delež okužb pri bolnikih, ki so prejemali Raptivo približno 25,7 %, v primerjavi z 22,3 % pri bolnikih, ki so prejemali placebo.
Platelet counts are recommended upon initiating and periodically while receiving Raptiva treatment.
Določanje števila trombocitov je priporočljivo na začetku zdravljenja in periodično med zdravljenjem z Raptivo.
The reconstituted solution is a clear to slightly opalescent, colourless to pale yellow solution, and should not be administered if it contains
Rekonstituirana raztopina je bistra do rahlo opalescentna, brezbarvna do bledo rumena raztopina in je ne smete uporabiti, če vsebuje delce ali ni bistra.
By this mechanism, efalizumab inhibits the binding of LFA-1 to ICAM-1, which interferes with T lymphocytes adhesion to other cell types.
S tem mehanizmom efalizumab inhibira vezavo LFA-1 na ICAM-1 (medcelična adhezijska molekula1), kar moti adhezijo limfocitov T na druge tipe celic.
After the powder has dissolved, check the resulting solution for particles and discoloration.
Ko se prašek raztopi, preglejte nastalo raztopino na prisotnost delcev ali spremembo barve.
If a patient develops PML, the dosing of Raptiva must be permanently discontinued.
Pri bolniku, ki razvije PML je treba zdravilo Raptiva dokončno ukiniti.
You must not receive certain types of vaccines during Raptiva treatment.
Med zdravljenjem z zdravilom Raptiva ne smete prejeti določenih vrst cepiv.
With the syringe still attached to the vial, check the syringe for air bubbles.
Z injekcijsko iglo še vedno zapičeno v vialo, preverite če so v injekcijski brizgi zračni mehurčki.
• Develop a diffuse skin rash or blisters in your oral cavity.
- Se vam v ustni votlini razvije difuzni kožni izpuščaj ali mehurji.
Raptiva has been used in combination with topical corticosteroids in psoriasis patients without any untoward effects nor with any observable significant beneficial effect of the combination therapy
Raptivo so uporabljali v kombinaciji s topikalnimi kortikosteroidi pri bolnikih s psoriazo brez kakršnihkoli neželenih učinkov kakor tudi brez opazne pomembne koristi kombiniranega zdravljenja v primerjavi z monoterapijo z efalizumabom.
Please check with your doctor if you receive other medicines to treat
S svojim zdravnikom preverite, če prejemate druga zdravila za zdravljenje psoriaze.
Polysorbate 20, histidine, histidine hydrochloride monohydrate and sucrose.
Polisorbat 20, histidin, histidinijev klorid monohidrat in saharoza.
There are no comparative data with Raptiva versus other systemic psoriasis therapies.
Ni primerjalnih podatkov o terapiji z Raptivo in drugimi sistemskimi terapijami psoriaze.
• Without removing the syringe, gently rotate the vial to dissolve the medicine in the solvent.
• Ne da bi odstranili injekcijsko brizgo, nežno zavrtite vialo, da raztopite zdravilo v vehiklu.
Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).
Zdravljenje odraslih bolnikov z zmerno do hudo kronično psoriazo s plaki, ki se ne odzivajo na, ali imajo kontraindikacije za, ali ne prenašajo drugega sistemskega zdravljenja, vključno s ciklosporinom, metotreksatom in PUVA (glejte poglavje 5.1 - Klinična učinkovitost).
Patients developing an infection during treatment with Raptiva should be monitored and according to severity Raptiva should be discontinued.
Bolnike, pri katerih se razvije okužba med zdravljenjem z Raptivo, moramo skrbno spremljati in glede na resnost okužbe prekiniti z uporabo Raptive.
Weight is the most significant covariate affecting efalizumab clearance.
Telesna masa je najbolj pomembna hkratna spremenljivka, ki vpliva na očistek efalizumaba.
He/she will determine whether to stop using Raptiva or continue treatment with closer
Zdravnik bo določil ali prekiniti z uporabo zdravila Raptiva ali nadaljevati zdravljenje z bolj
Moreover, an antibody analogue of efalizumab was shown to be excreted in milk of mice.
Poleg tega so dokazali izločanje analognega protitelesa efalizumabu v mleko pri miših.
If these manifestations occur, efalizumab should be stopped immediately, a platelet count should be performed and appropriate symptomatic treatment should be instituted immediately (see section 4.8).
Če se ti znaki pojavijo, moramo takoj prekiniti z uporabo efalizumaba in določiti število trombocitov v krvi ter takoj uvesti ustrezno simptomatsko zdravljenje (glejte poglavje 4.8).
• Back pain, joints pain, headache, vomiting, weakness, fatigue or rash.
- Bolečine v hrbtu, bolečine v sklepih, glavobol, bruhanje, oslabelost, utrujenost ali izpuščaj.
Within 5 to 8 weeks following the 12th and final dose of efalizumab administered at 1.0 mg/kg/wk, CD11a levels returned to within a range of ±25% of baseline values.
V 5 do 8 tednih po dvanajstem in zadnjem odmerku efalizumaba 1,0 mg/kg/teden, so se CD11a ravni povrnile na ±25 % izhodiščnih vrednosti.
Do not use Raptiva after the expiry date which is stated on the label and carton after EXP.
Zdravila Raptiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
In post-marketing surveillance, isolated cases of severe haemolytic anaemia have been reported during treatment with Raptiva.
V času spremljanja zdravila na trgu po pridobitvi dovoljenja za promet so poročali o posamičnih primerih hude hemolitične anemije med zdravljenjem z Raptivo.
In these studies, the incidence of other types of arthritis-related adverse events were similar between the Raptiva and
V teh študijah je bila incidenca neželenih dogodkov povezanih z drugimi tipi artritisa podobna v skupini z
- If you develop any of the signs and symptoms associated with a decrease in blood platelets, such as easy bleeding from the gums, bruising or pinpoint red spots on the skin, please tell your doctor immediately.
- Če razvijete kakršnekoli znake ali simptome povezane z zmanjšanjem števila trombocitov, kot so nagnjenost h krvavitvam iz dlesni, modrice ali točkaste rdeče pike na koži, prosimo da nemudoma obvestite svojega zdravnika.
Inject the solution by pushing gently on the plunger.
Raztopino injicirajte z blagim potiskanjem bata.
Colourless type I glass vial with a butyl rubber stopper, and aluminium seal fitted with a flip-off plastic cap.
Viale iz brezbarvnega stekla tipa I z bromobutilnim zamaškom in zaščitene z aluminijastim zapornim obročkom s pregibno plastično kapico, ki se odstrani na poteg.
- If you develop cancer while undergoing treatment, please contact your doctor who will determine if it is necessary for you to stop using Raptiva.
- Če se pri vas razvije rakasto obolenje med zdravljenjem z zdravilom Raptiva, se prosimo posvetujte z zdravnikom, ki bo določil, ali je potrebno da prenehate z uporabo zdravila Raptiva.
In large placebo-controlled clinical studies, approximately 20% of patients in excess of placebo reported flu-like symptoms including headaches, chills, fever, nausea and myalgia.
V velikih s placebom kontroliranih kliničnih študijah je približno 20 % bolnikov več kot pri placebu poročalo o gripi podobnih simptomih, vključno z glavobolom, mrzlico, zvišano telesno temperaturo, slabostjo in bolečinami v mišicah.
• The active substance is efalizumab, each vial contains a deliverable dose of 125 mg efalizumab.
• Zdravilna učinkovina je efalizumab, vsaka viala vsebuje razpoložljiv odmerek 125 mg
The most frequent symptomatic adverse drug reactions (ADRs) observed during Raptiva therapy were mild to moderate dose-related acute flu-like symptoms including headache, fever, chills, nausea and myalgia.
Najbolj pogosti simptomatski neželeni učinki (ADS - »adverse drug reactions«), ki so jih opazili med zdravljenjem z Raptivo so bili blagi do zmerni od odmerka odvisni akutni gripi podobni simptomi, vključno z glavobolom, zvišano telesno temperaturo, mrzlico, slabostjo in bolečinami v mišicah.
The powder is a white to off-white cake and the solvent is a colourless liquid.
Prašek je bel do belkaste barve v strjeni obliki in vehikel je brezbarvna tekočina.
Women should not breastfeed during treatment with Raptiva.
Ženske med zdravljenjem z Raptivo ne smejo dojiti.
In large placebo-controlled clinical studies approximately 4.5% of patients developed sustained elevation of alkaline phosphatase throughout Raptiva therapy compared to 1% in placebo patients.
V velikih s placebom kontroliranih kliničnih študijah je približno 4,5 % bolnikov razvilo vztrajno povečano raven alkalne fosfataze tekom celotnega zdravljenja z Raptivo v primerjavi z 1 % bolnikov, ki so prejemali placebo.
Driving and using machines The use of Raptiva is not expected to affect your ability to drive and use machines.
Vpliv na sposobnost upravljanja vozil in strojev Ni pričakovati, da bi uporaba zdravila Raptiva vplivala na vašo sposobnost upravljanja vozil in strojev.
In the first 12 weeks of placebo-controlled studies, arthritis and exacerbation or flare of arthritis were observed in 1.8% of Raptiva-treated patients and placebo-treated patients.
V prvih 12 tednih s placebom kontroliranih kliničnih študij, so opazili artritis in poslabšanje ali ponovni zagon artritisa pri 1,8 % bolnikov, ki so se zdravili z Raptivo ali so prejemali placebo.
INFORMATION IN BRAILLE raptiva 100 mg/ml
raptiva 100 mg/ml
In all studies, the primary endpoint was the proportion of patients with a ≥ 75% improvement in the Psoriasis Area and Severity Index score (a PASI 75 response) relative to baseline when assessed one week after a 12-week treatment course.
V vseh študijah je bil primarni cilj študije delež bolnikov z relativnim ≥ 75% izboljšanjem psoriaznih predelov in rezultatom indeksa resnosti (PASI 75 odziv) glede na izhodišče, ocenjeno teden dni po zaključku 12 tedenskega zdravljenja.
• Take the injection needle and, with its shield still in place, carefully screw it on to the syringe tip.
• Vzemite injekcijsko iglo in jo skupaj z varovalnim pokrovčkom previdno privijte na nastavek
Raptiva is for subcutaneous injection.
Raptivo se daje v obliki subkutane injekcije.
Withdraw the solution slowly into the syringe, taking more than the dose you need.
Počasi povlecite raztopino v injekcijsko brizgo, tako da iz viale odvzamete več raztopine, kot je potrebno za odmerek.
No studies have been conducted in patients with renal or hepatic impairment.
Študij z bolniki z ledvično ali jetrno okvaro niso izvedli.
• Pull off the cap covering the pre-filled syringe tip.
• Odtrgajte pokrovček, ki pokriva nastavek napolnjene injekcijske brizge.
Injection sites should be rotated.
Mesta injiciranja je treba izmenjavati.
Isolated cases have been observed during post-marketing surveillance.
Opazili so posamične primere v času spremljanja zdravila na trgu po pridobitvi dovoljenja za promet.
He/she will determine whether to monitor your treatment or whether it is necessary for you to stop using Raptiva.
Zdravnik bo določil ali nadzorovati vaše zdravljenje ali pa je potrebno, da prenehate z uporabo zdravila Raptiva.
PASI score (a PASI 50 response) relative to baseline after 12 weeks of treatment, the time-course of mean PASI percentage improvement from baseline, improvement in the Dermatology Life Quality Index (DLQI), Psoriasis Symptom Assessment (PSA), the Physician's Global Assessment (PGA) of change, change in the PASI thickness component, and change in the body surface area affected.
Sekundarni cilj študij je vključeval delež oseb, ki so dosegle oceno minimalno ali čisto pri statičnem globalnem pregledu pri zdravniku, celokupno hudost lezij (OLS), delež bolnikov z relativnim ≥ 50 % izboljšanjem PASI izvida (PASI 50 odziv) po 12 tednih zdravljenja, čas do dosege povprečnega izboljšanja PASI odziva glede na izhodišče, izboljšanje indeksa dermatološke kvalitete življanja (DLQI), oceno simptomov psoriaze (PSA), spremembo zdravniške globalne ocene (PGA), spremembo debeline komponent PASI in spremembo površine prizadetega predela telesa.
Following booster vaccination with tetanus toxoid (recall antigen), the ability to mount an immune response to the tetanus toxoid was preserved in those patients undergoing Raptiva therapy.
Pri bolnikih, ki so se zdravili z Raptivo, je bila po ponovnem cepljenju s tetanusnim toksoidom (recall antigen) sposobnost tvorbe imunskega odziva na tetanusni toksoid ohranjena.
At a dose of 1.0 mg/kg/wk subcutaneous efalizumab, lymphocyte levels returned to within 10% of baseline by 8 weeks post last dose.
Pri odmerku efalizumaba 1,0 mg/kg/teden subkutano, se je raven limfocitov povrnila na 10 % izhodiščne vrednosti v 8 tednih po zadnjem
NAME OF THE MEDICINAL PRODUCT Raptiva 100 mg/ml powder and solvent for solution for injection
IME ZDRAVILA Raptiva 100 mg/ml prašek in vehikel za raztopino za injiciranje
Over long term treatment, the incidence of serious infection was 1.8 per 100 patient years (see section 4.
Pri dolgotrajnem zdravljenju je bila incidenca resnih okužb 1,8 na 100 bolnikov-let.
In all five studies, patients randomized to the Raptiva group achieved statistically significantly better responses than placebo on the primary endpoint.
V vseh petih študijah so bolniki naključno zbrani v skupine, ki so prejemale zdravilo Raptiva dosegli statistično pomembno boljše rezultate za primarni cilj študij, kot bolniki, ki so prejemali placebo.
Mean steady state clearance is 24 ml/kg/day (range 5-76 ml/kg/day) at 1 mg/kg/ week subcutaneous.
Povprečni očistek v stanju dinamičnega ravnovesja je 24 ml/kg/dan (razpon 5-76 ml/kg/dan) pri odmerku
If you have injected more Raptiva than told by your doctor, please contact your doctor or pharmacist.
Če ste uporabili večji odmerek zdravila Raptiva, kot bi smeli Če ste si injicirali več zdravila Raptiva kot vam je predpisal zdravnik, se prosimo posvetujte z zdravnikom ali s farmacevtom.
Time to relapse (≥50% loss of improvement) was evaluated in Study ACD2058g and IMP 24011 for patients who were classified as responders (≥75% improvement on PASI) after 12 weeks of treatment.
V študiji ACD2058g in IMP24011 so ovrednotili čas do relapsa (≥50 % izguba izboljšanja) za bolnike, ki so jih opredelili kot odzivne (≥75 % izboljšanje PASI) po 12 tednih zdravljenja.
In the first 12 weeks of placebo-controlled studies, the rate of psoriasis adverse events was 3.2% in the Raptiva-treated patients and 1.4% in the placebo-treated patients.
V prvih 12 tednih s placebom kontroliranih kliničnih študij, je bil delež neželenih dogodkov psoriaze 3,2 % v skupini bolnikov, ki so prejemali Raptivo in 1,4 % v skupini bolnikov, ki so prejemali placebo.
In placebo controlled clinical trials, the overall incidences of malignancy (the majority of which were non-melanoma skin cancers) were similar in Raptiva-treated patients and in placebo-treated patients.
V s placebom kontroliranih kliničnih študijah, je bila celokupna incidenca malignih obolenj (večinoma nemelanomski kožni rak) podobna v skupinah bolnikov, ki so prejemali Raptivo in placebo.
Otherwise, the effects observed in non-clinical studies could be related to the pharmacology of
Sicer bi lahko bili učinki opaženi v predkliničnih študijah povezani s farmakologijo efalizumaba.
* Events identified during postmarketing surveillance
ALT *Dogodki opaženi v času spremljanja zdravila na trgu po pridobitvi dovoljenja za promet.
Reconstitution with the solvent yields a solution containing efalizumab at 100 mg/ml.
Po rekonstituciji z vehiklom nastane raztopina, ki vsebuje 100 mg/ml efalizumaba.
• Turn the vial upside down, with the syringe still attached.
• Obrnite vialo navzdol skupaj s pritrjeno injekcijsko brizgo.
About 5.7% of patients developed elevation in ALT during Raptiva therapy compared to 3.5% in placebo.
Približno 5,7 % bolnikov se je zvišala raven ALT med zdravljenjem z Raptivo v primerjavi s 3,5 % bolnikov, ki so prejemali placebo.
It appeared that the receptor mediated clearance of efalizumab was saturated when plasma efalizumab concentrations were above 1 μg/ml.
Pokazalo se je, da se od receptorja odvisni očistek efalizumaba nasiči, ko so plazemske koncentracije efalizumaba večje od
Leucocytosis and lymphocytosis: in large placebo-controlled and in long-term clinical studies, between 40 and 50% of patients developed sustained asymptomatic lymphocytosis during Raptiva therapy.
V velikih s placebom kontroliranih kliničnih študijah in v dolgotrajnih kliničnih študijah, je med 40 in 50 % bolnikov razvilo vztrajno asimptomatsko limfocitozo med zdravljenjem z Raptivo.